Beta talasemi minörde serum ürotensin II düzeyi incelenmesi

Abstract

Introduction and Purpose: Beta Thalassemia Minor (BTM) is a chronic hemolytic anemia due to impaired hemoglobin structure due to poor production of beta globulin chain in hemoglobin structure. Cerebrovascular and cardiovascular events in BTM have been shown in studies performed less frequently. Mechanism has not been fully elucidated. Urotensin is the most potent known vasoconstrictor. Studies have shown that Urotensin II is elevated in essential hypertension, congestive heart failure, metabolic syndrome, and carotid artery stenosis. We also thought that the possible low UII levels in BTM might be a minor effect of cerebrovascular and cardiovascular pathologies in our study and we aimed to investigate serum urotensin II level in BTM patients. Material and Methods: The subjects included in the study were divided into two groups, the BTM group (Group 1-n: 45) and the healthy controls (Group 2-n: 46). Comorbidities and drug use that are known to affect the level of urotensin II and drug use have been identified as exclusion criteria for the study. Urotensin II measurements were performed using ELISA kits. Results: In the BTM group (Group 1), 46 people were included in the study group (Group 2). There was no difference between the two groups in terms of gender, age, and BMI (p: 0.69, p: 0,166, p: 0,145). Plasma UII level averages were 352.65 ± 130.46 ng / L in Group 1 and 222.88 ± 80.44 ng / L in Group 2. Group 1 was statistically significantly higher (p <0.001). UII levels were significantly correlated with HbA2 in the positive direction (p: <0.001, r: 0.482). There was no relationship between UII levels, age, sex, and BMI. Conclusion: In our study, we had the opposite result of our hypothesis. We expected to find the UII molecule low in Group 1. We think that high UII levels in the BTM group are highly detected as hemolysis and anemia secondary to ineffective erythropoiesis in BTM. The correlation of UII level with HbA2 supports this. We think that more comprehensive studies on the effect of other protective factors should be made in less frequent ischemic vascular pathologies in BTM.

{{abstract}}